The drug in question, a selective aldose reductase inhibitor called govorestat, was being evaluated in the phase 2/3 Inspire study of 56 patients with a progressive neuromuscular disease called ...

Govorestat is a central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) being developed for the treatment of multiple rare diseases including Charcot-Marie-Tooth Sorbitol ...

The results are based on analysis of data from the phase 3, randomized, placebo-controlled ARISE-HF (Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure; ClinicalTrials ...

The drug candidate acts by targeting aldose reductase. It is administered through an oral and subcutaneous route. It was under development for congestive heart failure in adults. Applied Therapeutics ...

New York-based Applied was seeking approval for the aldose reductase inhibitor govorestat in people with classic galactosemia, a rare disease that causes developmental delays, speech problems and ...

Applied’s drug, called govorestat, inhibits the enzyme aldose reductase, which converts galactose into that toxic substance, galactitol. The company evaluated the drug in a Phase 3 trial, results from ...

The Aldose Reductase pipeline drugs market research report outlays comprehensive information on the Aldose Reductase targeted therapeutics, complete with analysis by indications, stage of development, ...

MONTREAL — An investigational oral aldose reductase inhibitor, govorestat, significantly improved primary outcomes of physical function and serum sorbitol reduction in patients with sorbitol ...

Among individuals with well-controlled T2DM with stage B HF and impaired exercise capacity, 15 months of an aldose reductase inhibitor (AT-001) did not result in higher peak VO 2 vs. placebo. Future ...

USA: In a significant stride towards combating the complications of diabetes, a recent randomized trial has unveiled promising results regarding the efficacy of a selective aldose reductase inhibitor ...